j Abstract Peroxiredoxin II, a cytosolic isoform of the antioxidant enzyme family, has been implicated in cancer-associated cell death and apoptosis, but its functional role in the heart remains to be elucidated. Interestingly, the expression levels of peroxiredoxin II were decreased in mouse hearts upon ischemia-reperfusion, while they were elevated in two genetically modified hyperdynamic hearts with phospholamban ablation or protein phosphatase 1 inhibitor 1 overexpression. To delineate the functional significance of altered peroxiredoxin II expression, adenoviruses encoding sense or antisense peroxiredoxin II were generated; cardiomyocytes were infected, and then subjected to H 2 O 2 treatment to mimic oxidative stress-induced cell death and apoptosis. H 2 O 2 stimulation resulted in a significant decrease of endogenous peroxiredoxin II expression, along with reduced cell viability in control cells. However, overexpression of peroxiredoxin II significantly protected from H 2 O 2 -induced apoptosis and necrosis, while downregulation of this enzyme promoted the detrimental effects of oxidative stress in cardiomyocytes. The beneficial effects of peroxiredoxin II were associated with increased Bcl-2 expression, decreased expression of Bax and attenuated activity of caspases 3, 9 and 12. Furthermore, there were no significant alterations in the expression levels of the other five isoforms of peroxiredoxin, as well as active catalase or glutathione peroxidase-1 after ischemia-reperfusion or H 2 O 2 treatment. These findings suggest that peroxiredoxin II may be a unique antioxidant in the cardiac system and may represent a potential target for cardiac protection from oxidative stress-induced injury.
reperfusion injury, myocardial stunning, apoptosis and arteriosclerosis [36] . Accumulation of ROS in mitochondria can lead to apoptotic cell death [55] and ROS may also have direct effects on cellular structure and function, including myocardial remodeling and failure [27, 47] . Under physiological conditions, the toxic effects of ROS can be prevented by such scavenging enzymes as superoxide dismutase (SOD), glutathione peroxidase (GHPx) and catalase, as well as other non-enzymatic antioxidants. However, when the production of ROS becomes excessive, oxidative stress might have a harmful effect on the functional and structural integrity of the heart [40, 47] .
Recently, redox signaling and peroxiredoxin family enzymes have been suggested to play a role in mediating the antioxidant effects in the heart [11, 25, 37] . Ablation of peroxiredoxin VI, rendered the heart vulnerable to ischemia-reperfusion [32] , while overexpression of the mitochondrial-specific peroxiredoxin III prevented left ventricular remodeling and failure after myocardial infarction in mice [29] . Interestingly, we have found that the expression levels of peroxiredoxin II, another member of the peroxiredoxin family, were increased in the hyperdynamic hearts of two genetically altered mouse models: phospholamban knockout (PLN KO) and protein phosphatase 1 inhibitor 1 overexpression (I-1 OE) [6, 34] . Taken together, these studies prompt us to further investigate the functional significance of peroxiredoxin II in the heart.
Peroxiredoxin II is a member of an antioxidant enzyme family (other members are peroxiredoxin I, III, IV, V and VI), which has the ability to reduce H 2 O 2 and hydroperoxides into water and alcohol, respectively. Most of the known mammalian peroxiredoxins, except the peroxiredoxin VI isoform, utilize thioredoxin as an immediate electron donor; hence they are known as thioredoxin peroxidases. Peroxiredoxin II is a 25 kDa protein, which has a high affinity for H 2 O 2 (Km for H 2 O 2 £ 10 lM), similar to GHPx (Km for H 2 O 2 is approximately 1 lM) and is abundant in the cytosol from a wide range of tissues, making it a major regulator of the H 2 O 2 signal in the cell, compared to catalase (Km for H 2 O 2 around 1 mM) [49, 51] . Peroxiredoxin II knockout mice exhibited hemolytic anemia, indicating that peroxiredoxin II plays a major role in protecting red blood cells from oxidative stress in mice [24] . Peroxiredoxin II deficiency also resulted in increased production of H 2 O 2 , enhanced activation of platelet-derived growth factor (PDGF) receptor and phospholipase Cc1, subsequently leading to increased cell proliferation and migration in response to PDGF [5] . Overexpression of peroxiredoxin II protected leukemia cells from apoptosis [54] , while antisense peroxiredoxin II enhanced radiation-induced cancer cell death [33] .
However, the functional significance of this isoform in the heart is not currently known. To determine whether peroxiredoxin II plays a role in cardiac oxidative stress, the levels of this enzyme were altered in isolated cardiomyocytes, which were then subjected to H 2 O 2 treatment. Our results provide the first evidence that overexpression of peroxiredoxin II protects cardiomyocytes from oxidative stress-induced cell death and apoptosis, whereas downregulation of peroxiredoxin II greatly impairs these protective effects, suggesting a major role for this isoform in cardiac protection against oxidative stress.
Methods j Mouse models
Phospholamban (PLN) deficient and protein phosphatase 1 inhibitor 1 (I-1) overexpression mice were generated in our lab [26, 35] . All experimental procedures and protocols used in this study were reviewed and approved by the University of Cincinnati Institutional animal care and use committee and are in accordance with the National Institutes of Health ''Guide for the care and use of laboratory animals'' (NIH publication No. 85-23, revised 1996).
j Global ischemia-reperfusion injury ex vivo
Global ischemia-reperfusion injury was performed in isolated perfused hearts by Langendorff mode, as previously described [14] . After a 20-min equilibration period, the hearts were subjected to 40 min of no-flow global ischemia, followed by 60 min of reperfusion. Hearts were then snap frozen in liquid nitrogen and homogenized in 1· Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA) supplemented with 1 mM PMSF and complete protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN) for quantitative immunoblotting. j Adenoviral-mediated gene transfer
Peroxiredoxin II cDNA was purchased from Open Biosystem. Recombinant adenoviruses with sense or antisense of the peroxiredoxin II cDNA were generated, using the pAd.Track-CMV/pAdEasy-1 system [12] . The shuttle vector pAdTrack-CMV and the adenoviral backbone vector pAdEasy-1 were generously provided by Dr. Bert Vogelstein from the Johns Hopkins Oncology Center. Adenoviruses were amplified in HEK293 cells, purified with ViraKit from Virapur and titered according to the standard procedure of Adeno-X TM rapid titer kit from Clontech. After 2 h of plating, cardiomyocytes were infected with sense or antisense peroxiredoxin II adenoviruses (Ad.prxII or Ad.prxII-AS) or control Ad.GFP at a multiplicity of infection (MOI) of 200 for 2 h before the addition of a suitable volume of complete DMEM medium (DMEM containing 2 mg/ml BSA, 2 mM L-carnitine, 5 mM creatine, 5 mM taurine, 100 IU/ml penicillin and 100 lg/ml streptomycin) [22] . The content of cardiomyocyte thiobarbituric acid substances (TBARS) was determined, as previously described [15] . Cardiomyocyte plasma membrane integrity was assessed by measuring lactate dehydrogenase (LDH) release into the culture medium with an in vitro LDH assay kit (Sigma-Aldrich).
j Quantitative immunoblotting
Cultured myocytes were harvested and lysed for 20 min at 4°C in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 10% glycerol, 0.4 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, 0.5 mM DTT, and 2 ll/ml protease inhibitor cocktail). After 10 min of centrifugation at 10,000g, the supernatants were obtained and used in subsequent experiments. For each protein, equal amounts of samples (5-120 lg) were analyzed by SDS-PAGE. After transfer to membranes, quantitative immunoblotting analysis was performed with the corresponding primary antibodies [peroxiredoxins I to IV from Alexis Biochemicals (Lausen, Switzerland), peroxiredoxins V and VI from Abcam (Cambridge, MA), catalase and GHPx-1 from Santa Cruz Biotechnology (Santa Cruz, CA), Bcl-2 and Bax from Invitrogen (South San Francisco, CA); cleaved caspase 3 (Asp175), caspase 9, and caspase 12 from Cell Signaling (Danvers, MA); and calsequestrin (CSQ) from Affinity Bioreagents (Golden, CO)] at a 1:500 to 1:5,000 dilution. This was followed by incubation with a secondary antibody conjugated with horseradish peroxidase at a 1:5,000 dilution. Visualization was achieved using SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL) or ECL-PLUS Western Blotting Detection kit (Amersham Pharmacia Biotech, Piscataway, NJ). The intensities of the bands were determined by the AlphaEaseFC TM software. For each protein, the densitometric values from nontreatment controls were arbitrarily converted to 100%, and the values of samples from the other groups were normalized accordingly and expressed as percentile changes. CSQ was used as an internal standard.
j Statistics
Data are expressed as mean ± SE. Comparisons between two groups were performed by Student t test (from Microsoft Office, Excel), while one-way ANOVA (from GraphPad Prizm4) was used for multigroup comparison. Results were considered statistically significant at P < 0.05.
Results j Increased expression of peroxiredoxin II in the hyperdynamic hearts of two mouse models
Cardiac proteomics-based analysis of our two models with significantly enhanced cardiac function, the PLN KO and the protein phosphatase 1 inhibitor 1 overexpression (I-1 OE) mice, revealed increases in the levels of peroxiredoxin II [6, 34] . Further quantitative immunoblotting showed that the levels of peroxiredoxin II expression were enhanced by 2.5-fold in the PLN-KO and by 2.4-fold in the I-1 OE, compared to age-matched wild types ( Fig. 1a and 1b) . These results indicate that peroxiredoxin II, a relatively new antioxidant protein, may play an important functional role in the heart.
j Alterations of cardiac peroxiredoxin II expression in ex vivo cardiac ischemia-reperfusion injury
It has been reported that ROS or oxidative stress are significantly increased upon cardiac ischemia-reperfusion injury. To investigate whether peroxiredoxin II expression is also altered, mouse hearts were perfused ex vivo in a Langendorff mode and subjected to 40 min of ischemia followed by 60 min of reperfusion. Interestingly, the peroxiredoxin II levels were significantly decreased to about 65% of pre-ischemic values, upon ischemia-reperfusion (Fig. 1c) . These data suggest that decreased expression of peroxiredoxin II may contribute to the cardiac ischemicreperfusion injury. (Fig. 2a ) and the levels of peroxiredoxin II were examined. In the cells infected with Ad.prxII, the level of peroxiredoxin II was increased by 1.5-fold, while this protein was decreased by 70% in the Ad.prxII-AS cells, compared to the Ad.GFP group (Fig. 2b) . However, no apparent morphological alterations or differences in the number of adherent cells and rod-shaped cells were observed among the three groups. To determine the effect of peroxiredoxin II overexpression or downregulation on cell death and apoptosis, the infected cardiomyocytes were treated with H 2 O 2 and cell viability as well as cell nuclear fragmentation were examined. Upon H 2 O 2 treatment, cell viability was significantly decreased to the same extent in both control and Ad.GFP infected cells. More importantly, cell viability was restored upon overexpression of peroxiredoxin II. In contrast, downregulation of peroxiredoxin II significantly reduced the cell survival, compared to control cells (Fig. 2c) . Accordingly, cell nuclear fragmentation was significantly increased by~2.8-fold in both control and Ad.GFP infected cells. Overexpression of peroxiredoxin II reduced cell fragmentation to even lower levels than control or non-treated cells, while downregulation of peroxiredoxin II had opposite effects (Fig. 2d) To further determine the effect of overexpression or downregulation of peroxiredoxin II on cardiomyocyte membrane integrity before and after 50 lM H 2 O 2 treatment, the levels of TBARS were assessed. We found that overexpression or downregulation of peroxiredoxin II did not influence the intracellular TBARS under basal condition (data now shown). However, after H 2 O 2 treatment, the levels of TBARS were increased by 14 or 15-fold in the control and Ad.GFP infected myocytes, compared to untreated cardiomyocytes (Fig. 3a) . Overexpression of peroxiredoxin II significantly attenuated this increase, while downregulation of peroxiredoxin II resulted in further increases of TBARS (Fig. 3a) . Accordingly, evaluation of the levels of lactate dehydrogenase (LDH) release, another parameter in evaluating cell membrane integrity, revealed similar results. Specifically, overexpression or downregulation of peroxiredoxin II did not play a role in LDH release under basal condition (data now shown). However, H 2 O 2 treatment increased the LDH levels by threefold in control groups (Fig. 3b) , and this effect was attenuated by overexpression of peroxiredoxin II, while downregulation of this enzyme resulted in increased LDH release (Fig. 3b) . Thus, increases in peroxiredoxin II expression in cardiomyocytes decrease TBARS and LDH levels, while downregulation of peroxiredoxin II has opposite effects in H 2 O 2 -treated cardiomyocytes. Calsequestrin was used as a loading control (n = 7 hearts for each group). e Cardiomyocyte viability was analyzed by MTT assay after H 2 O 2 (50 lM) treatment for 2 h; n = 6 hearts for each group. Values are mean ± SE, *P < 0.05, compared to control j Peroxiredoxin II overexpression increases Bcl-2, inhibits Bax and decreases active caspases 3, 9 and 12 expression in cardiomyocytes
To further investigate the possible mechanisms underlying the protection of cell death and apoptosis by peroxiredoxin II overexpression, the expression levels of key apoptotic-related proteins were quantitatively assessed. H 2 O 2 treatment was associated with significant decreases in the expression of the anti-apoptotic protein Bcl-2 in non-infected or Ad.GFP infected myocytes. However, overexpression of peroxiredoxin II prevented the Bcl-2 decrease, rather than further increased its levels. Accordingly, downregulation of peroxiredoxin II resulted in augmented decreases of Bcl-2, compared to the control treated groups (Fig. 4a, b) . Moreover, the wellknown pro-apoptotic proteins Bax, active caspases 3, 9 and 12 were significantly increased upon H 2 O 2 treatment (Fig. 4a, b ), which were prevented by peroxiredoxin II overexpression. Consequently, reduction in peroxiredoxin II levels had opposite results and promoted further increases in these proapoptotic proteins, compared to controls (Fig. 4a, b) . These results suggest that the mechanisms underlying the protection of peroxiredoxin II are associated with increased expression of the anti-apoptotic protein Bcl-2, and decreased expression of the proapoptotic proteins Bax and active caspases 3, 9 and 12. To further determine the specificity of decreased expression of peroxiredoxin II in the heart upon ischemia-reperfusion injury or in the cardiomyocytes with H 2 O 2 treatment, protein levels of the other five peroxiredoxin isoforms, including: peroxiredoxin I, III, IV, V and VI were examined. As shown in Fig. 5a d, we did not find any significant differences in these proteins, except peroxiredoxin I, which was decreased to 80% in the hearts after ischemia-reperfusion, compared to pre-ischemia-reperfused hearts. Similarly, the peroxiredoxin I expression was downregulated to 72% in H 2 O 2 -treated cardiomyocytes, compared to controls. In addition, the active forms of two representative cytosolic house-keeping proteins, catalase and GHPx-1, were examined. There was no significant difference in the expression of catalase and GHPx-1 after ischemia-reperfusion injury. In cardiomyocytes treated with H 2 O 2 , the levels of catalase were not altered, while GHPx-1 levels were significantly depressed (Fig. 5c-d) . Although it is not currently clear why the levels of GHPx-1 were not consistently decreased in isolated hearts or isolated cardiomyocytes, these findings suggest that peroxiredoxin I and GHPx-1 may also play a role in cardiac ischemia-reperfusion or H 2 O 2 -induced injury. We further evaluated the role of overexpression or downregulation of peroxiredoxin II on the expression of peroxiredoxin I, catalase and GHPx-1 in cardiomyocytes with or without H 2 O 2 treatment. Under basal condition, these proteins' expression showed no significant difference among Ad.GFP, Ad.prxII and Ad.prxII-AS-infected cardiomyocytes (Fig. 6a, b) . Furthermore, H 2 O 2 treatment did not elicit any significant alterations in the levels of catalase, compared to control cells (Fig. 6a, b) . In addition, the decreased expression levels of peroxiredoxin I and GHPx-1 remained the same among the cells infected with Ad.-prxII or Ad.prxII-AS, compared to controls (Fig. 6a,  b) . These data indicate that overexpression or downregulation of peroxiredoxin II does not alter the expression levels of peroxiredoxin I, catalase and GHPx-1 before and after H 2 O 2 treatment, suggesting a 
Discussion
The present study provides the first evidence that peroxiredoxin II may play an important protective role in cardiac oxidative stress. Increases in the levels of peroxiredoxin II protected the cardiomyocytes against oxidative stress-induced apoptosis and cell death by H 2 O 2 , the major source of ROS in cardiomyocytes under stress conditions [23] . These beneficial effects of peroxiredoxin II in cardiomyocytes were associated with increases in the anti-apoptotic protein Bcl-2 and decreases in the pro-apoptotic protein Bax expression, as well as attenuation of the activity of active caspases 3, 9 and 12. Figure 7 summarizes the possible effects of peroxiredoxin II in oxidativestress-induced cardiac injury. Consistent with our findings, overexpression of peroxiredoxin I and peroxiredoxin II protected thyroid cells from H 2 O 2 -induced apoptosis, which was also associated with reduced Bax levels [23] . Furthermore, overexpression of human peroxiredoxin II in Molt-4 leukemia cells inhibited release of cytochrome c from mitochondria to cytosol and lipid peroxidation, therefore protecting the cells from apoptosis in a similar manner as Bcl-2 [54] . Interestingly, peroxiredoxin II could also prevent H 2 O 2 accumulation in these leukemic cells, suggesting that it may function upstream of Bcl-2 [54] .
To further investigate the specificity of the loss of peroxiredoxin II during cardiac ischemia-reperfusion injury and in response to H 2 O 2 , we examined the expression levels of the other 5 isoforms of the peroxiredoxin family, as well as two representative cytosolic house keeping proteins: catalase and GHPx-1. Consistent with other previous reports [29, 32, 50] , there were no significant differences in the expression levels of most of these proteins. Furthermore, overexpression or downregulation of peroxiredoxin II did not change the expression of the cytosolic house keeping proteins, catalase and GHPx-1, with or I/R  #1  #2  #3  #4  #1  #2  #3  #4  #1  #2  #3  #4  #1  #2  #3 GHPx-1 prxl prxlII prxlV prxV prxVI catalase GHPx-1 Fig. 5 Effect of cardiac ischemia-reperfusion injury and H 2 O 2 stimulation on the expression of peroxiredoxin family members, catalase and glutathione peroxidase (GHPx-1). a and b WT hearts were subjected to ex vivo Langendorff perfusion, as described in Fig. 1 . The levels of the other five peroxiredoxin family members, including peroxiredoxin I, III, IV, V and VI, as well as two representative cytosolic house keeping proteins: catalase and GHPx-1 were determined. c and d Cardiomyocytes were isolated and cultured for 24 h, then treated with 50 lM H 2 O 2 for 2 h. Cells were harvested, lysed and processed for western blot to examine the expression levels of the same proteins as those in (a) and (b); n = 4 hearts for each group, Values are mean ± SE, *P £ 0.05, Vs. per I/R or control cells without oxidative stress stimulation. Interestingly, the expression levels of peroxiredoxin I were found to be significantly decreased after ischemia-reperfusion injury and after H 2 O 2 treatment, indicating the potential effect of this protein involved in the process of oxidative stress-related cardiac injury. However, peroxiredoxin II overexpression or downregulation did not further influence the expression of preoxiredoxin I. These findings indicate that the antioxidant properties of peroxiredoxin II in the heart might be independent of other antioxidant enzymes, suggesting a unique effect of peroxiredoxin II in the process of cardiac ischemia-reperfusion injury or H 2 O 2 -induced cell death. The decreased expression of peroxiredoxin II found in the hearts of ischemia-reperfusion injury or cardiomyocytes after H 2 O 2 treatment may involve leakage of this enzyme into the extracellular fluid and then elimination during reperfusion of the hearts or culturing of the cells [49] . Although the exact mechanisms and interactions among various antioxidants are not fully understood, it is possible that one antioxidant may equilibrate with another to establish a cellular redox potential and that all endogenous antioxidants may work in conjunction with one another to protect against oxidative stress [8] . It is also possible that certain antioxidants act as the first line of defense against oxidative stress in ischemiareperfusion, while other antioxidants may only act later during severe oxidative stress [8] . It is unclear if the loss of peroxiredoxin II is based on its oxidation by H 2 O 2 or excessive ROS and subsequent degradation by the proteasome. However, it has been reported that silica, one of the fibrogenic agents, induces rapid degradation of peroxiredoxin I and peroxiredoxin II in Rat2 cells along with significant production of ROS in the cells. The degradation of peroxiredoxin enzymes was insensitive to the proteasome inhibitors: MG132 and lactacystin [43] . Another report showed opposite results, as cardiomyocytes treated with MG132 exhibited induced antioxidant protein expression, including peroxiredoxin I and SOD-1 [10] . Although experimental studies with proteasome inhibitor strongly suggest the role of proteasomes in the process of ischemia-reperfusion injury [1, 2, 16, 39] , there are still some controversial reports. One study has shown that reperfusion of isolated hearts with MG132 improves posthypoxic function of excised isolated papillary muscles [45] . However, this occurred after a prehypoxic delay of at least 30 minutes with demonstrable increases in heat shock proteins, but no determination of myocardial proteasome activity. The same group also showed that incubation of vascular smooth muscle cells with low concentrations of proteasome inhibitors results in upregulation of proteasome subunit transcription and translation [30] , indicating the possibility that the previous results were related to increases in proteasome activity. Conversely, it was reported that preischemic treatment of isolated rat hearts with MG132 results in a dose-dependent decrease in postischemic function, but increased levels of ubiquitinated proteins [38] . In addition, pretreatment with the more specific inhibitor, lactacystin, according to a protocol that decreased preischemic proteasome activity by 40%, failed to have any effects on postischemic function [9] . Taken together, these studies indicate the complicated regulation for cardiac ischemia-reperfusion injury with multiple factors involved. Furthermore, several studies have demonstrated the complex modification of cardiac peroxiredoxins during oxidative stress. Schroder et al. [41] reported that H 2 O 2 induces an array of changes in the myocardium, including formation of disulfide bonds that were intermolecular for peroxiredoxin I, II and III, but intramolecular within peroxiredoxin V. Peroxiredoxin oxidation was also associated with movement from the cytosol to the membrane and myofilament-enriched fraction. Jang et al. [21] suggested that two cytosolic yeast peroxiredoxins: peroxiredoxin I and peroxiredoxin II, which display diversity in structure and apparent molecular weight (MW), act alternatively as peroxidases and molecular chaperones. The peroxidase function predominates in the lower MW forms, whereas the chaperone function predominates in the higher MW complexes. Oxidative stress and heat shock exposure of yeast cause the protein structures of cytosolic peroxiredoxin I and II to shift from low MW species to high MW complexes. Moon et al. [31] also indicated that human peroxiredoxin II assumes a high MW complex structure, which has a highly efficient chaperone function upon exposure to oxidative stress. However, the subsequent removal of stressors induces the dissociation of this protein structure into low MW proteins and triggers a chaperone-to-peroxidase functional switch. These studies indicate a complicated intracellular molecular interaction, which needs to be further investigated. It has been reported that short term exposure of cardiomyocytes to H 2 O 2 results in cardiomyocyte death due to necrosis as well as apoptosis [28] . Cardiomyocyte necrosis induced by H 2 O 2 is associated with cell membrane phospholipid peroxidation by ROS. Hydroxyl radicals generated from the decomposition of H 2 O 2 through the iron dependent Fenton reaction initiate lipid peroxidation by reacting with methylene groups of polyunsaturated fatty acids [3] . Our results suggest that hydroxyl radical-mediated lipid peroxidation and LDH release, may contribute to H 2 O 2 -induced cell necrosis. Increases in peroxiredoxin II appear to prevent cell necrosis by attenuating TBARS and LDH release, while reduction in peroxiredoxin II levels have opposite effects. The antiapoptotic effects of peroxiredoxin II overexpression were associated with increases in Bcl-2 and preserved Bax levels after H 2 O 2 treatment, leading to inhibition of caspases 3 and 9 activation (Fig. 7) . Consequently, there was reduced cell death and apoptosis, suggesting that the cardioprotective effects of peroxiredoxin II are at least partially associated with the mito- (Fig. 7) . The in vivo role of peroxiredoxin II in oxidative stress-induced cardiomyocyte death and apoptosis is currently unclear. Neonatal cardiomyocytes exposed to H 2 O 2 for 2 hours exhibited increased transcripts of peroxiredoxin II and V, which shifted to lower pI values upon two-dimensional gel electrophoresis, suggesting complex regulation of these two enzymatic activities in cardiomyocytes [7] . It could be hypothesized that overexpression of peroxiredoxin II in the hyperdynamic PLN KO and protein phosphatase 1 inhibitor-1 overexpressing (I-1 OE) hearts may serve as an important cardioprotective mechanism, allowing for normal life-span in these models [44] . Interestingly, in vitro studies have shown that cotransfection of PLN and HAX-1, another anti-apoptotic protein, in HEK293 cells enhances protection from hypoxia-reoxygenation-induced cell death and apoptosis [48] , which suggest a potential involvement of PLN in cardiomyocyte apoptosis. However, the potential association between peroxiredoxin II and PLN in the cardiac anti-apoptotic pathways needs to be further examined.
A major consequence of increased cardiac metabolism associated with PLN KO and I-1 OE mice is the significant increase in formation of oxidative radicals at the level of the cellular NAD(P)H oxidases in the mitochondrial electron transport chain [18] , which represents a major source of free radical generation in the cell. The increased expression of peroxiredoxin II (the cytosolic form of the peroxiredoxin family) in these hyperdynamic mouse hearts may represent an essential adaptation to neutralize oxidative stress generated by increased oxide-reduction activity. This energetic adaptation may also be important in heart failure, where multiple anatomic and molecular factors converge to increase the net energetic demands on the heart. Growing evidence suggests an important role for increased oxidative stress in adverse left ventricular remodeling after myocardial infarction [17] . It has been shown that various antioxidant approaches (vitamin C, vitamin E, probucol, dimethylthiourea or genetic manipulation) can ameliorate this adverse remodeling. The beneficial effects of these experimental approaches extend to improved contractile function, reduced left ventricular dilatation and lower mortality, especially in a short term. However, long term effects of these treatments seem disappointing [42] . A better understanding of the precise roles of oxidative stress and redox signaling pathways may therefore provide the basis for new therapeutic strategies [42] . The protective effects of peroxiredoxin II from oxidative stress-induced cell injury observed in this study may yield new insights in the treatment of cardiac oxidative stress. 
